This article refers to:
In the article “The impact of biologic response modifiers on hepatitis B virus infection”, published in the April 2011 issue of Expert Opinion on Biological Therapy (Expert Opin Biol Ther (2011) 11(4):533-544), an error was made during the production process.
In Section 2.4 (Anti-CD20 therapy), the following sentence:
“In HBcAb-negative, HBsAb-positive, HBsAb-positive patients close clinical and serological monitoring for HBV reactivation has been recommended.”
Should have read:
“In HBsAg-negative, HBcAb-positive, HBsAb-positive patients, close clinical and serological monitoring for HBV reactivation has been recommended.”
Informa Healthcare would like to apologise for this error and for any confusion caused.